Innovar Treatment for Meniere's Disease

Patients with intractable vertigo due to clinical Meniere's disease were offered treatment with Innovar, a neurolept analgesic. The patients were from a single clinical practice, had failed conventional dietary and medical treatment and were eligible on clinical grounds for endolymphatic sac su...

Full description

Saved in:
Bibliographic Details
Published in:Acta oto-laryngologica 1999-03, Vol.119 (2), p.189-193
Main Author: Gates, George A.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Analgesics - therapeutic use
Biological and medical sciences
Droperidol - therapeutic use
Ent. Stomatology
Female
Fentanyl - therapeutic use
Follow-Up Studies
Humans
Male
Medical sciences
Meniere Disease - drug therapy
Middle Aged
Pharmacology. Drug treatments
Risk Factors
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with intractable vertigo due to clinical Meniere's disease were offered treatment with Innovar, a neurolept analgesic. The patients were from a single clinical practice, had failed conventional dietary and medical treatment and were eligible on clinical grounds for endolymphatic sac surgery. After a follow-up of 2-8 years, 58% of patients had long-lasting relief of vertigo. Hearing was not affected. Risk factors for a favorable response were male gender, fluctuating hearing, and early stage of the disorder. Innovar is a safe, cost-effective second-line therapy for patients with Meniere's disease who have failed conventional first-line medical therapy.
ISSN:0001-6489
1651-2251
DOI:10.1080/00016489950181648